Patents by Inventor Mark A. Vaeck
Mark A. Vaeck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9901609Abstract: The application relates to medicinal plant extracts and their use in the treatment of diseases, more particularly diseases caused by the presence of stones in ducts of the digestive system.Type: GrantFiled: October 14, 2014Date of Patent: February 27, 2018Assignees: AVICENNA DEVELOPMENT, UNIVERSITY OF ANTWERPInventors: Luc Pieters, Sandra Apers, Mart Theunis, Mark Vaeck, Khalil El Mazouari, Yahia Cherrah
-
Patent number: 9725522Abstract: In one aspect, the invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules. In one aspect, the present invention relates to a method wherein an immunoglobulin single variable domain (such as a Nanobody) and/or construct thereof are absorbed in pulmonary tissue. More particularly, the invention provides systemic delivery of an immunoglobulin single variable domain and/or construct thereof via the pulmonary route.Type: GrantFiled: March 8, 2016Date of Patent: August 8, 2017Assignee: Ablynx N.V.Inventors: Marie-Paule Lucienne Armanda Bouche, Peter Vanlandschoot, Erwin Sablon, Erik Depla, Stefan De Buck, Xavier Saelens, Bert Schepens, Karen Silence, Mark Vaeck, Paul M. P. Van Bergen En Henegouwen, Hans De Haard
-
Patent number: 9701717Abstract: The application provides Alphabodies that specifically bind to IL-23, as well as to polypeptides that comprise or essentially consist of such Alphabodies. Also provided herein are nucleic acids encoding such Alphabodies; to methods for preparing such Alphabodies and polypeptides; and in particular to pharmaceutical compositions, that comprise such Alphabodies, polypeptides, nucleic acids and/or host cells.Type: GrantFiled: October 22, 2013Date of Patent: July 11, 2017Assignee: COMPLIX NVInventors: Johan Desmet, Maria Paulina Henderikx, Klaartje Somers, Stefan Loverix, Mark Vaeck, Ignace Lasters
-
Publication number: 20160280799Abstract: In one aspect, the invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules. In one aspect, the present invention relates to a method wherein an immunoglobulin single variable domain (such as a Nanobody) and/or construct thereof are absorbed in pulmonary tissue. More particularly, the invention provides systemic delivery of an immunoglobulin single variable domain and/or construct thereof via the pulmonary route.Type: ApplicationFiled: March 8, 2016Publication date: September 29, 2016Applicant: Ablynx NV.Inventors: MARIE-PAULE LUCIENNE ARMANDA BOUCHE, Peter Vanlandschoot, Erwin Sablon, Erik Depla, Stefan De Buck, Xavier Saelens, Bert Schepens, Karen Silence, Mark Vaeck, Paul M. P. Van Bergen En Henegouwen, Hans De Haard
-
Publication number: 20160213726Abstract: The application relates to medicinal plant extracts and their use in the treatment of diseases, more particularly diseases caused by the presence of stones in ducts of the digestive system.Type: ApplicationFiled: October 14, 2014Publication date: July 28, 2016Applicants: UNIVERSITY OF ANTWERP, AVICENNA DEVELPMENTInventors: Luc Pieters, Sandra Apers, Mart Theunis, Mark Vaeck, Khalil El Mazouari, Yahia Cherrah
-
Patent number: 9320792Abstract: In one aspect, the invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules. In one aspect, the present invention relates to a method wherein an immunoglobulin single variable domain (such as a Nanobody) and/or construct thereof are absorbed in pulmonary tissue. More particularly, the invention provides systemic delivery of an immunoglobulin single variable domain and/or construct thereof via the pulmonary route.Type: GrantFiled: February 7, 2013Date of Patent: April 26, 2016Assignee: Ablynx N.V.Inventors: Marie-Paule Lucienne Armanda Bouche, Peter Vanlandschoot, Erwin Sablon, Erik Depla, Stefan De Buck, Xavier Saelens, Bert Schepens, Karen Silence, Mark Vaeck, Paul M. P. Van Bergen En Henegouwen, Hans De Haard
-
Patent number: 9243065Abstract: The invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further relates to a method for delivering therapeutic molecules to the interior of cells. The invention further relates to polypeptide constructs including VHH directed against EGFR.Type: GrantFiled: June 19, 2009Date of Patent: January 26, 2016Assignee: Ablynx N.V.Inventors: Karen Silence, Mark Vaeck, Paul M. P. Van Bergen En Henegouwen
-
Publication number: 20150266925Abstract: The application provides Alphabodies that specifically bind to IL-23, as well as to polypeptides that comprise or essentially consist of such Alphabodies. Also provided herein are nucleic acids encoding such Alphabodies; to methods for preparing such Alphabodies and polypeptides; and in particular to pharmaceutical compositions, that comprise such Alphabodies, polypeptides, nucleicacids and/or host cells.Type: ApplicationFiled: October 22, 2013Publication date: September 24, 2015Applicant: COMPLIX NVInventors: Johan Desmet, Maria Paulina Henderikx, Klaartje Somers, Stefan Loverix, Mark Vaeck, Ignace Lasters
-
Publication number: 20140363434Abstract: The application provides polypeptides comprising or essentially consisting of at least one Alphabody, wherein said Alphabody is capable of internalization into a cell and specifically binds to an intracellular target molecule. The application further provides nucleic acids encoding such polypeptides; methods for preparing such polypeptides; host cells expressing or capable of expressing such polypeptides; compositions, and in particular to pharmaceutical compositions, that comprise such polypeptides, nucleic acids and/or host cells; and uses of such polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes.Type: ApplicationFiled: January 4, 2013Publication date: December 11, 2014Applicant: COMPLIX NVInventors: Ignace Lasters, Mark Vaeck, Johan Desmet, Jürgen Debaveye, Sabrina Deroo, Stefan Loverix
-
Publication number: 20110184145Abstract: The invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules.Type: ApplicationFiled: April 1, 2011Publication date: July 28, 2011Applicant: ABLYNX N.V.Inventors: KAREN SILENCE, MARK VAECK, PAUL M. P. VAN BERGEN EN HENEGOUWEN
-
Publication number: 20110184151Abstract: The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Epidermal Growth Factor Receptor. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation. It further relates to protocols for screening for agents that modulate the Epidermal Growth Factor Receptor, and the agents resulting from said screening. The invention further a method for delivering therapeutic molecules to the interior of cells.Type: ApplicationFiled: April 1, 2011Publication date: July 28, 2011Applicant: Ablynx N.V.Inventors: Toon Laeremans, Paul M. P. Van Bergen En Henegouwen, Karen Silence, Mark Vaeck
-
Publication number: 20110123529Abstract: The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Epidermal Growth Factor Receptor. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation. It further relates to protocols for screening for agents that modulate the Epidermal Growth Factor Receptor, and the agents resulting from said screening. The invention further a method for delivering therapeutic molecules to the interior of cells.Type: ApplicationFiled: January 28, 2011Publication date: May 26, 2011Applicant: Ablynx N.V.Inventors: Toon Laeremans, Paul M. P. Van Bergen En Henegouwen, Karen Silence, Mark Vaeck
-
Publication number: 20100040613Abstract: The invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules.Type: ApplicationFiled: June 19, 2009Publication date: February 18, 2010Applicant: Ablynx N.V.Inventors: Karen Silence, Mark Vaeck, Paul M.P. Van Bergen En Henegouwen
-
Publication number: 20100021459Abstract: The invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules.Type: ApplicationFiled: June 19, 2009Publication date: January 28, 2010Applicant: Ablynx N.V.Inventors: Karen Silence, Mark Vaeck, Paul M. P. Van Bergen En Henegouwen
-
Publication number: 20100003249Abstract: The invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules.Type: ApplicationFiled: June 19, 2009Publication date: January 7, 2010Applicant: Ablynx N.V.Inventors: Karen Silence, Mark Vaeck, Paul M. P. Van Bergen En Henegouwen
-
Publication number: 20100003253Abstract: The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Epidermal Growth Factor Receptor. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation. It further relates to protocols for screening for agents that modulate the Epidermal Growth Factor Receptor, and the agents resulting from said screening.Type: ApplicationFiled: April 28, 2009Publication date: January 7, 2010Applicant: Ablynx N.V.Inventors: Toon Laeremans, Paul M.P. Van Bergen En Henegouwen, Karen Silence, Mark Vaeck
-
Publication number: 20100003248Abstract: The invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules.Type: ApplicationFiled: June 19, 2009Publication date: January 7, 2010Applicant: Ablynx N.VInventors: Karen Silence, Mark Vaeck, Paul M. P. Van Bergen En Henegouwen
-
Publication number: 20090324512Abstract: The invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules.Type: ApplicationFiled: June 19, 2009Publication date: December 31, 2009Applicant: Ablynx N.V.Inventors: Karen Silence, Mark Vaeck, Paul M. P. Van Bergen En Henegouwen
-
Publication number: 20060115470Abstract: The invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention furthe relates to anti-IgE therapeutic molecules.Type: ApplicationFiled: November 7, 2003Publication date: June 1, 2006Applicant: Ablynx N. V.Inventors: Karen Silence, Mark Vaeck, Paul Van Bergen En Henegouwen
-
Patent number: 5545565Abstract: Novel transformation vectors containing novel chimeric genes allow the introduction of exogenous DNA fragments coding for polypeptide toxins produced by Bacillus thuringiensis or having substantial sequence homology to a gene coding for a polypeptide toxin as described herein and expression of the chimeric gene in plant cells and their progeny after integration into the plant cell genome. Transformed plant cells and their progeny exhibit stably inherited polypeptide toxin expression useful for protecting said plant cells and their progeny against certain insect pests and in controlling said insect pests.Type: GrantFiled: May 22, 1995Date of Patent: August 13, 1996Assignee: Plant Genetic Systems, N.V.Inventors: Henri M. J. De Greve, Maria B. L. F. Salgado, Marc C. E. Van Montagu, Mark A. Vaeck, Marcus F. O. Zabeau, Jan J. A. Leemans, Hermanus F. P. Hofte